Avadel Pharmaceuticals (AVDL) Income from Continuing Operations (2016 - 2021)
Historic Income from Continuing Operations for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' Income from Continuing Operations fell 89424.15% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 146337.92%. This contributed to the annual value of -$85.5 million for FY2021, which is 125357.59% down from last year.
- Avadel Pharmaceuticals' Income from Continuing Operations amounted to -$23.1 million in Q4 2021, which was down 89424.15% from -$25.7 million recorded in Q3 2021.
- Avadel Pharmaceuticals' Income from Continuing Operations' 5-year high stood at $30.9 million during Q2 2020, with a 5-year trough of -$63.9 million in Q4 2018.
- Its 5-year average for Income from Continuing Operations is -$9.2 million, with a median of -$11.0 million in 2020.
- In the last 5 years, Avadel Pharmaceuticals' Income from Continuing Operations skyrocketed by 52769.89% in 2017 and then plummeted by 89424.15% in 2021.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Income from Continuing Operations stood at -$8.2 million in 2017, then plummeted by 674.52% to -$63.9 million in 2018, then increased by 28.68% to -$45.5 million in 2019, then skyrocketed by 94.89% to -$2.3 million in 2020, then crashed by 894.24% to -$23.1 million in 2021.
- Its Income from Continuing Operations was -$23.1 million in Q4 2021, compared to -$25.7 million in Q3 2021 and -$23.3 million in Q2 2021.